Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasing clinical and socio-economic burden. One quarter of the world’s population is estimated to have NAFLD and its incidence is steadily rising. In addition, NAFLD is the fastest growing cause of age-adjusted liver cancer deaths worldwide. In this Masterclass video, Dr Stuart McPherson briefly discusses key aspects of the diagnosis and management of NAFLD, including updates such as the 2022 joint-BSG/BASL consensus recommendations on the quality standards for the management of NAFLD.

Dr Stuart McPherson is a Consultant Hepatologist, Honorary Clinical Senior Lecturer, and Head of Department for Liver Medicine at the Newcastle upon Tyne Hospitals. He completed undergraduate medical training at St Andrews and Manchester Universities and subsequently undertook specialist training in Glasgow and Newcastle. In addition, Dr McPherson spent two years in Brisbane, Australia researching hepatitis C and fatty liver disease. Apart from ongoing research in the early diagnosis of NAFLD and the prevention of cirrhosis, he also serves as the Chair of the BSG/BASL NAFLD Special Interest Group.